Viridian Therapeutics, Inc./DE — Earnings
Most recent reported period: FY2026 (Q1) (filed for period ending 2026-03-31) · sourced from SEC EDGAR
Next earnings (estimated): Tue, June 30, 2026 — ~54 days away. Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2026-03-31 | $141K | ↑+95.8% | $-105M | ↓-20.7% | -82389.4% |
| 2025-12-31 | $132K | ↑+83.3% | — | — | — |
| 2025-09-30 | $71M | ↑+81958.1% | $-35M | ↑+54.9% | -56.7% |
| 2025-06-30 | $75K | ↑+4.2% | $-101M | ↓-55.0% | -142356.0% |
| 2025-03-31 | $72K | ↑+0.0% | $-87M | ↓-79.0% | -130369.4% |
| 2024-12-31 | $72K | ↑+0.0% | — | — | — |
| 2024-09-30 | $86K | ↑+19.4% | $-77M | ↓-60.9% | -97069.8% |
| 2024-06-30 | $72K | ↑+0.0% | $-65M | ↓-18.0% | -100259.7% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2026 (Q1)
Revenue
$141K
↑+95.8% +$69K YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
VRDN Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyVRDN Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics